在治疗尿路感染中，影响对萘啶酸产生耐药性的因素。
Factors governing the emergence of resistance to nalidixic acid in treatment of urinary tract infection.
作者信息
Greenwood D, O'Grady F
出版信息
Antimicrob Agents Chemother. 1977 Dec;12(6):678-81. doi: 10.1128/AAC.12.6.678.
Abstract
Cultures of Escherichia coli were exposed to nalidixic acid in an in vitro model in which the conditions of drug-organism interaction resembled those of bacterial cystitis treatment. Results obtained in this way suggested that emergence of bacterial resistance should not be a major problem in treatment of uncomplicated urinary infection; such cases might indeed respond to a less intensive course of treatment than is usual. More prolonged, high-dosage therapy with nalidixic acid may be required for patients with more complicated infections if the risk of failure from the emergence of bacterial resistance is to be minimized.
摘要
在一个体外模型中，将大肠杆菌培养物暴露于萘啶酸中，该模型中药物与生物体的相互作用条件类似于细菌性膀胱炎的治疗情况。通过这种方式获得的结果表明，在单纯性泌尿系统感染的治疗中，细菌耐药性的出现不应成为一个主要问题；此类病例可能确实对强度低于常规的治疗疗程有反应。如果要将因细菌耐药性出现而导致治疗失败的风险降至最低，对于感染情况更复杂的患者，可能需要更长时间、更高剂量的萘啶酸治疗。
相似文献
1
Factors governing the emergence of resistance to nalidixic acid in treatment of urinary tract infection.在治疗尿路感染中，影响对萘啶酸产生耐药性的因素。
Antimicrob Agents Chemother. 1977 Dec;12(6):678-81. doi: 10.1128/AAC.12.6.678.
2
Nalidixic acid in urinary tract infections with particular reference to the emergence of resistance.萘啶酸在尿路感染中的应用，特别提及耐药性的出现。
Scand J Infect Dis. 1974;6(3):259-64. doi: 10.3109/inf.1974.6.issue-3.09.
3
Rifampicin plus nalidixic acid: a rational combination for the treatment of urinary infection.利福平加萘啶酸：治疗泌尿系统感染的合理组合。
J Antimicrob Chemother. 1978 Nov;4(6):533-8. doi: 10.1093/jac/4.6.533.
4
[Nalidixic acid (Wintomylon) and bacterial resistance to antibiotics in urinary tract infections].[萘啶酸（温托米隆）与尿路感染中细菌对抗生素的耐药性]
Hinyokika Kiyo. 1968 Jun;14(6):351-6.
5
The responses of Escherichia coli to nalidixic acid.大肠杆菌对萘啶酸的反应。
Chemotherapy. 1978;24(4):249-58. doi: 10.1159/000237789.
6
The assessment of antimicrobial activity in an in-vitro model of the treatment of bacterial cystitis.在细菌性膀胱炎治疗的体外模型中对抗菌活性的评估。
J Antimicrob Chemother. 1984 May;13 Suppl B:43-8. doi: 10.1093/jac/13.suppl_b.43.
7
Nalidixic acid in urinary infection.萘啶酸在泌尿系统感染中的应用
Bull Calcutta Sch Trop Med. 1968 Jan;16(1):11-2.
8
Sulphadimidine and nalidixic acid therapy in urinary-tract infections in general practice.
Practitioner. 1971 Dec;207(242):819-26.
9
Effect of a three-day course of nalidixic acid in the frequency-dysuria syndrome with significant bacteriuria in women.
Scand J Infect Dis. 1983;15(1):71-4. doi: 10.3109/inf.1983.15.issue-1.11.
10
Nalidixic acid and oxolinic acid in the treatment of chronic bacteriuria.萘啶酸和恶喹酸治疗慢性菌尿症
Ann Intern Med. 1969 Apr;70(4):713-21. doi: 10.7326/0003-4819-70-4-713.
引用本文的文献
1
Comparison of norfloxacin versus nalidixic acid in therapy of acute urinary tract infections.诺氟沙星与萘啶酸治疗急性尿路感染的比较。
Can J Infect Dis. 1990 Summer;1(2):35-40. doi: 10.1155/1990/482960.
2
Antibacterial activity of ciprofloxacin in conventional tests and in a model of bacterial cystitis.
Eur J Clin Microbiol. 1984 Aug;3(4):351-4. doi: 10.1007/BF01977493.
3
Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections.西诺沙星。其药理学特性及治疗尿路感染疗效的综述。
Drugs. 1983 Jun;25(6):544-69. doi: 10.2165/00003495-198325060-00002.
4
Studies on the emergence of resistance to lomefloxacin in vitro.
Eur J Clin Microbiol Infect Dis. 1989 Aug;8(8):741-5. doi: 10.1007/BF01963766.
5
Activity of flumequine against Escherichia coli: in vitro comparison with nalidixic and oxolinic acids.氟甲喹对大肠杆菌的活性：与萘啶酸和恶喹酸的体外比较。
Antimicrob Agents Chemother. 1978 Mar;13(3):479-83. doi: 10.1128/AAC.13.3.479.
本文引用的文献
1
NALIDIXIC ACID IN URINARY INFECTIONS.萘啶酸在尿路感染中的应用
Br Med J. 1963 Nov 23;2(5368):1311-4. doi: 10.1136/bmj.2.5368.1311.
2
NALIDIXIC ACID IN INFECTIONS OF URINARY TRACT. LABORATORY AND CLINICAL INVESTIGATIONS.萘啶酸在尿路感染中的应用。实验室及临床研究。
Br Med J. 1963 Nov 23;2(5368):1308-10. doi: 10.1136/bmj.2.5368.1308.
3
A critical evaluation of nalidixic acid in urinary-tract infections.对萘啶酸治疗尿路感染的批判性评价。
N Engl J Med. 1966 Nov 17;275(20):1081-9. doi: 10.1056/NEJM196611172752001.
4
Estimation of residual urine volume with 131 I-hippuran.
Br J Urol. 1968 Apr;40(2):196-201. doi: 10.1111/j.1464-410x.1968.tb09874.x.
5
Bacteriologic and pharmacodynamic aspects of nalidixic acid.萘啶酸的细菌学和药效学方面
J Urol. 1970 Dec;104(6):903-13.
6
Nalidixic acid and oxolinic acid in the treatment of chronic bacteriuria.萘啶酸和恶喹酸治疗慢性菌尿症
Ann Intern Med. 1969 Apr;70(4):713-21. doi: 10.7326/0003-4819-70-4-713.
7
Observations on bacterial sensitivities to nalidixic acid and critical comments on the 6-centre survey.关于细菌对萘啶酸敏感性的观察及对六中心调查的批判性评论。
Postgrad Med J. 1971 Sep;47:Suppl:16-8.
8
A twelve channel bacterial growth monitoring system.一个十二通道细菌生长监测系统。
Biomed Eng. 1973 Dec;8(12):514-5 passim.
9
Comparison of the responses of Escherichia coli and proteus mirabilis to seven beta-lactam antibodies.大肠杆菌和奇异变形杆菌对七种β-内酰胺抗体反应的比较。
J Infect Dis. 1973 Aug;128(2):211-22. doi: 10.1093/infdis/128.2.211.
10
Zotero 插件